HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome	Abnormalities, Multiple, Angelman syndrome, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Imprinting Disorders, central nervous system disorder, chromosomal disorder, hereditary disease, movement disorder, nervous system disorder	Active, not recruiting	Phase 1 / Phase 2	2026-08-20		NCT05127226

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ionis Pharmaceuticals, Inc.	22

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Azienda Ospedaliera Universitaria Pisana	Pisa	Italy	13
Boston Children's Hospital	Boston	United States	20
Colorado Children's Hospital Research Institute	Aurora	United States	2
Necker-Enfants Malades Hospital	Paris	France	3
Rady Children's Hospital	San Diego	United States	52
Rush University Medical Center	Chicago	United States	283
Sheba Medical Center	Ramat Gan	Israel	25
STRONG Group University of Oxford	Oxford	United Kingdom	1
Sydney Children's Hospital, Kids Cancer Centre	Randwick	Australia	1
Texas Children's Hospital	Houston	United States	187
University of North Carolina at Chapel Hill School of Medicine	Carrboro	United States	3